Trial · NCT01791894
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
NCT01791894, Phase 1, Phase 2, Completed, Stanford University; results first posted 2016-10-28
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma. Trials, record NCT01791894. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01791894
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
- NCT number
- NCT01791894
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
- Interventions
- arsenic trioxide
- First posted
- 2013-02-15
- Last updated
- 2018-06-08
- Results first posted
- 2016-10-28
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Biomarker (GLI2 Protein) Levels | baseline to day 33 | |
| Secondary | Patients With Stable Disease Post Treatment | After 3 cycles of treatment (approx. 61 days) | Number of patients with stable disease post treatment by RECIST criteria |
| Secondary | Patients With Progressive Disease Post Treatment by RECIST Criteria | After 3 treatment cycles (approx. 61 days) | Patients with a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Secondary | Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 | Baseline to cycle 3 |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Biomarker (GLI2 Protein) Levels | baseline to day 33 | We recruited patients with biopsy-confirmed metastatic basal cell carcinoma who were had progressed on SMO inhibitors such as vismodegib (GDC 0449), IPI- 926, LEQ506 and LDE225. | percentage decrease | MEAN |
| SECONDARY | Patients With Stable Disease Post Treatment | After 3 cycles of treatment (approx. 61 days) | 4 patients completed 3 cycles of treatment | participants | NUMBER |
| SECONDARY | Patients With Progressive Disease Post Treatment by RECIST Criteria | After 3 treatment cycles (approx. 61 days) | participants | NUMBER | |
| SECONDARY | Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 | Baseline to cycle 3 | number of occurrences | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Biomarker (GLI2 Protein) Levels | Treatment (Arsenic Trioxide) | 75 | Standard Deviation 11 | percentage decrease | |
| Patients With Stable Disease Post Treatment | Treatment (Arsenic Trioxide) | 3 | participants | ||
| Patients With Progressive Disease Post Treatment by RECIST Criteria | IV ATO | 1 | participants | ||
| Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 | IV ATO | 2 | number of occurrences |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | IV ATO | 5 | |
| Overall Study | COMPLETED | IV ATO | 4 | |
| Overall Study | NOT COMPLETED | IV ATO | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | grade 1 asymptomatic atrial flutter | Cardiac disorders | Treatment (Arsenic Trioxide) | 1 | 5 | 1 |
| other | transaminitis | Investigations | Treatment (Arsenic Trioxide) | 1 | 5 | 1 |
| serious | grade 3 infection | Blood and lymphatic system disorders | Treatment (Arsenic Trioxide) | 1 | 5 | 1 |
| serious | grade 4 leukopenia | Blood and lymphatic system disorders | Treatment (Arsenic Trioxide) | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Arsenic Trioxide) | ||
| Total, other adverse events | Treatment (Arsenic Trioxide) | 1 | 5 |
| Total, serious adverse events | Treatment (Arsenic Trioxide) | 1 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01791894
GET https://conductscience.org/api/trials/v1/NCT01791894/registered